✨ Free AI Report
Cellectis S.A.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Cellectis S.A.
Company Research

Cellectis S.A.: Business Overview, Financials & Competitive Analysis

Cellectis S.A. scores 6/10 on the AskCyborg Cyborg Score (Solid). Clinical-stage gene-editing biotech with differentiated allogeneic CAR-T platform and promising early efficacy data, but meaningful revenue remains multi-year away. Recent Phase 1 BALLI-01 study data for lasme-cel (UCART22) demonstrated 68-100% efficacy rates depending on dose escalation. The company has strong intellectual property and technology platforms. However, as a clinical-stage company.

What is Cellectis S.A.'s industry? Cellectis S.A. (cellectis.com) operates in Biotechnology - Gene Therapy & Immuno-Oncology (CAR-T Cell Therapy). AskCyborg classifies Cellectis S.A. under Biotechnology - Gene Therapy & Immuno-Oncology (CAR-T Cell Therapy) in its company registry.

Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company pioneers an allogeneic approach for CAR-T immunotherapies in o...

6/ 10Solid

Cyborg Score thesis

Clinical-stage gene-editing biotech with differentiated allogeneic CAR-T platform and promising early efficacy data, but...

Read the full analyst-debate transcript →
Industry Biotechnology - Gene Therapy & Immuno-Oncology (CAR-T Cell Therapy)
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 7, 2026
AI-Verified Research
30+ Page Report

Get the Latest Cellectis S.A. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Cellectis S.A.

AskCyborg analysts argue the bull and bear cases for Cellectis S.A. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Cellectis S.A. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Cellectis S.A. Overview

Pro stress-test →

Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company pioneers an allogeneic approach for CAR-T immunotherapies in oncology, developing off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. This represents a significant innovation versus conventional autologous approaches.

Strategic Profile

Pro stress-test →

Cellectis has 25 years of expertise in gene editing based on its flagship TALEN® technology and pioneering electroporation system PulseAgile. The company develops a new generation of immunotherapy product candidates with additional safety and efficacy attributes equipped to resist mechanisms that inhibit immune system activity. The allogeneic CAR-T approach offers significant competitive advantages over standard autologous therapies.

Competitive Landscape

Pro stress-test →

Cellectis competes in the CAR-T therapy space after pivoting from meganuclease technology to immunotherapy focus. The company faces competition from both established CAR-T players (Juno/Celgene, Kite/Gilead) and emerging allogeneic platforms. Cellectis' differentiated allogeneic approach and proprietary TALEN editing technology provide competitive advantages in manufacturing efficiency and off-the-shelf deployment.

Industry Context

Cellectis S.A. operates in Biotechnology - Gene Therapy & Immuno-Oncology (CAR-T Cell Therapy).

Key facts

Founded: 1999 · Headquarters: Paris, France · Employees: 216 · Revenue: N/A · Market cap: $122.11M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Cellectis S.A..

  • UCART22 (lasme-cel) Phase 1 data showed 68% overall response rate and up to 100% efficacy in target Phase 2 population
  • Cellectis' allogeneic approach uses T-cells from healthy donors with gene editing to disable genes causing graft-versus-host disease, offering off-the-shelf manufacturing advantages
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • November 2025Published Nature Communications article on non-viral CssDNA gene insertion technology for hematopoietic stem cells
  • October 2025Presented Phase 1 BALLI-01 data for lasme-cel (UCART22) with promising efficacy in heavily pretreated B-ALL patients
  • +1 moreTrack every material event for Cellectis S.A. as it happens. Explore monitoring →
Get alerted when Cellectis S.A. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Autologous CAR-T therapiesTraditional patient-derived CAR-T cell therapies→Autologous CAR-T therapiesCommercially approved autologous CAR-T for hematologic malignancies→Allogeneic cell therapy platformOff-the-shelf cell therapy development→

Compare Cellectis S.A. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Cellectis S.A. operates in Biotechnology - Gene Therapy & Immuno-Oncology (CAR-T Cell Therapy). See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Gene Therapy & Immuno-Oncology (CAR-T Cell Therapy) research →
NEW · MCP server

Ask your AI assistant about Cellectis S.A.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Cellectis S.A. and its top competitor on Cyborg Score”
“What did Cellectis S.A. do this quarter?”
“Is Cellectis S.A. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Cellectis S.A. do?+
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company pioneers an allogeneic approach for CAR-T immunotherapies in o...
What is Cellectis S.A.'s Cyborg Score?+
Cellectis S.A. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Cellectis S.A.'s main competitors?+
Named competitors include Autologous CAR-T therapies, Autologous CAR-T therapies, Allogeneic cell therapy platform. The full competitive landscape is in the AskCyborg report.
How can I get the full Cellectis S.A. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Cellectis S.A. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Cellectis S.A. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.